4beta-hydroxycholesterol in Cirrhosis

4beta-hydroksikolesteroli Maksakirroosissa

Status

Suspended

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04199910

Enrollment

120

Registered

2019-12-16

Start date

2019-12-01

Completion date

2027-12-31

Last updated

2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Liver

Brief summary

The aim is to evaluate the levels of oxysterols and especially 4beta-hydroxycholesterol in patients with liver cirrhosis. Three cirrhosis cohorts are recruited: patients treated with spironolactone, patients treated with rifaximin, patients without spironolactone or rifaximin. Also three other control cohorts are recruited: patients with pneumonia, patients with Crohn's disease, patients with ulcerative colitis. The effect of the cirrhosis and its medications spironolactone and rifaximin are compared to control groups.

Interventions

OTHERThere is no intervention, only research blood samples are collected

Research blood samples collected

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with cirrhosis, pneumonia, Crohn's disease or colitis ulcerosa * Treated in the ward 42 of the Oulu University Hospital

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Blood 4beta-hydroxycholesterol concentration	At the time point of the blood collection - cross-sectional. One day.	Blood 4beta-hydroxycholesterol concentration

Countries

Finland

Contacts

PRINCIPAL_INVESTIGATORJanne Hukkanen, MD

Oulu University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026